Table of Contents
What is Zepbound?
Zepbound (tirzepatide) is a GIP and GLP-1 receptor agonist designed for weight loss in adults dealing with obesity or overweight conditions accompanied by weight-related medical issues. Its efficacy in weight management is enhanced when combined with a balanced diet and regular exercise. Zepbound facilitates weight loss by curbing appetite and delaying the movement of food from the stomach to the small intestine, promoting a quicker and prolonged feeling of fullness.
Zepbound Administration
Administered as a once-weekly subcutaneous injection using a pre-filled single-dose pen, Zepbound shares the active ingredient tirzepatide with Mounjaro, both products being manufactured by Eli Lilly and Company.
FDA Approval and Indications
Zepbound gained FDA approval on November 8, 2023, for chronic weight management in adults with obesity (BMI of 30 kg/m2 or greater) or those overweight (BMI of 27 kg/m2 or greater) with associated medical problems. These problems may include hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease. Its usage is recommended alongside diet modifications and increased physical activity.
Weight Loss Results on Zepbound
In a clinical trial (SURMOUNT-1, NCT04184622), patients on Zepbound (tirzepatide) experienced significant weight loss over 72 weeks. The 5mg weekly dose resulted in an average weight loss of 16.1 kg (35.5 lb), the 10mg dose showed 22.2 kg (48.9 lb) loss, and the 15mg dose exhibited an average loss of 23.6 kg (52.0 lb). Comparatively, the placebo group lost 2.4 kg (5.3 lb). Individual results may vary.
Mounjaro and Zepbound, sharing the same active ingredient (tirzepatide), are FDA-approved for distinct purposes. Mounjaro is intended for type 2 diabetes, while Zepbound is approved for weight loss. Both are administered as weekly subcutaneous injections, available in similar strengths.
Zepbound Side Effects
Common side effects affecting 5% or more patients include abdominal pain, burping, constipation, diarrhea, dyspepsia, fatigue, gastroesophageal reflux disease, hair loss, hypersensitivity reactions, injection site reactions, nausea, and vomiting.
Serious side effects may include allergic reactions, pancreatitis, severe stomach problems, eye side effects, thyroid tumor symptoms, gallbladder problems, or kidney problems.
Warnings
Immediate medical attention is required for signs of an allergic reaction or symptoms of pancreatitis. Zepbound should be discontinued if thyroid tumor symptoms emerge. It is contraindicated in individuals with a family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2).
Usage Guidelines
Prescription adherence is crucial. Zepbound is a subcutaneous injection typically given once a week, with dose adjustments based on the initial 2.5 mg dose and subsequent increments. The injection site can be rotated among the thigh, abdomen, or upper arm.
Available Strengths of Zepbound Pens
Zepbound is available in pre-filled single-dose pens with strengths of 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, and 15 mg/0.5 mL.
Missed Dose and Overdose
If a dose is missed, it can be taken within four days, otherwise, skip and resume the regular schedule. Overdose management involves contacting the poison control helpline or emergency services if severe symptoms occur.
Interactions
Potential interactions exist with various medications, necessitating communication with healthcare providers. Birth control pills’ efficacy may decrease, requiring alternative methods for four weeks after starting Zepbound. Caution is needed when combining it with other diabetes treatments to manage the risk of hypoglycemia.
Storage Instructions
Store Zepbound in the refrigerator (36⁰F to 46⁰F) and protect from freezing. Single-dose pens can be stored at room temperature (up to 86⁰F) for up to 21 days if necessary.
Ingredients
Active ingredient: tirzepatide; Inactive ingredients: sodium chloride, sodium phosphate dibasic heptahydrate, and water for injection, with possible pH adjustments using hydrochloric acid solution and/or sodium hydroxide solution.
